
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
Ridwan Alam, MD, a urology resident at Johns Hopkins Brady Urological Institute, discusses the abstract, “Investigation of race and associated socioeconomic factors in survival outcomes for patients with renal cell carcinoma,” which he presented at the 2022 AUA Annual Meeting (